MET and obesity due to melanocortin 4 receptor deficiency: Selective small-molecule antagonists of PAR4 (Merali et al. 2023, Nash et al. 2024) and c-met (Kudo et al. 2020, Wu et al. 2023) which are currently undergoing clinical evaluation therefore offer new therapeutic perspectives for the treatment of obesity-related atrial cardiomyopathy and its sequelae.